University of Massachusetts
Worcester, Massachusetts, 01605, United States
NCT Number: NCT03065075
To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 3
Worcester, Massachusetts, 01605, United States
Several tools can be used to evaluate for ureteral patency during urogynecologic procedures. Typically, surgeons use urine dyes such as methylene blue, indigotindisulfonate sodium, or phenazopyridine, with the latter being restricted to oral administration. However in June 2014, the two U.S. manufacturers of indigotindisulfonate sodium stopped producing the medication and there is no prospect that it will be returning soon. Phenazopyridine is an over-the-counter medication (Azo-Gesic, Baridium, Urinary Pain Relief) that has been used safely for decades as a bladder analgesic and taints the urine orange.
Over the past few months, increasing evidence suggests that phenazopyridine may reduce transient postoperative urinary retention. Transient urinary retention is common after urogynecologic surgery and is assessed postoperatively by performing a void trial (VT) prior to discharge. In a study designed to determine the time from administration of oral phenazopyridine to visualize dye from the ureters, Propst et al incidentally found that 38% of patients (19 of 49) failed postoperative VTs without phenazopyridine, but only 19% (9 of 47) failed with phenazopyridine, p=0.04. Most recently, a study by Duenas-Garcia et al designed to examine local anesthetics and urinary retention in subjects undergoing midurethral slings found that phenazopyridine decreased the VT failure rate from 30% to 8% (5). The investigators hypothesize that giving a dose of phenazopyridine the morning after surgery will significantly reduce the rate of postoperative urinary retention in women undergoing prolapse repair.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Phenazopyridine 200 mg on morning of postoperative day 1
Other names: Pyridium
Time frame: postoperative day 1
Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.
Time frame: postoperative day 1
Rate of postoperative urinary retention after pelvic organ prolapse surgery as determined by those who failed a standardized void trial. A successful void trial is defined as a postvoid residual of less than half of the voided volume.
University of Massachusetts, Worcester
Other
Acronym: EPOV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05887375
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Columbia, Missouri, United States
View Trial DetailsNCT07304583
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Samsun, Atakum, Turkey (Türkiye)
View Trial DetailsNCT06241703
Colorectal Neoplasms, Digestive System Diseases
Changchun, Jilin, China
View Trial DetailsNCT06344884
Catheter Site Pain, Postoperative Urinary Tract Infection
Raleigh, North Carolina, United States
View Trial Details